Sickle cell disease in Sri Lanka: Clinical and molecular basis and the unanswered questions about disease severity.

CURRENT STATUS: UNDER REVIEW

Thamal Darshana
University of Sri Jayewardenepura
darshana@sjp.ac.lk
Corresponding Author
ORCiD: https://orcid.org/0000-0003-3156-8734

Dayananda Bandara
National Thalassaemia centre, Teaching hospital - Kurunegala

Upul Nawarathne
Department of Pediatrics, Teaching hospital - Kurunegala

Udaya de Silva
Thalassaemia Unit, Teaching hospital - Anuradhapura

Yasinta Costa
Department of Haematology, Teaching hospital - Ragama

Kalavitigoda Pushpakumara
Department of Pediatrics, District General Hospital - Matara

Sumithra Pathirage
Department of Pediatrics, District General Hospital - Hambantota

Seuwandi Basnayake
Department of Haematology, District General Hospital - Monaragala

Chamila Epa
Department of Haematology, Teaching hospital - Batticaloa

Pradeepa Dilrukshi
Department of Haematology, District General Hospital, Ampara

Maheshaka Wijayawardena
Department of Pediatrics, District General Hospital, Ampara
Angela A. Anthony
Department of Clinical Sciences, Eastern University, Sri Lanka

Rexan Rodrigo
Thalassaemia adult and adolescent care centre, Teaching hospital - Ragama

Aresha Manamperi
Molecular Medicine Unit, University of Kelaniya

Frances Smith
Molecular Pathology Department, Viapath at King's College Hospital, London

Angela Allen
Weatherall Institute of Molecular Medicine

Stephan Menzel
School of cancer and pharmaceutical sciences, The Rayne Institute, King's college, London

David Rees
King's College Hospital Department of Haematological Medicine

Anuja Premawardhena
Department of Medicine, University of Kelaniya

DOI:
10.21203/rs.2.23845/v1

SUBJECT AREAS
Internal Medicine

KEYWORDS
Sickle cell, Sri Lanka, Genetic, Clinical, Severity
Abstract

Background Though case reports and limited case series of Sickle cell disease in Sri Lanka have been reported previously, no attempt has been made hitherto to undertake a comprehensive genotypic-phenotypic analysis of this “rare” group of patients.

Results All accessible Sickle cell disease patients, totaling 60, including, 51 Sickle β-thalassaemia and 9 homozygous sickle patients were enrolled from seven thalassaemia treatment centres between December 2016 - March 2019. The majority of patients were of Sinhalese ethnicity (n=52, 86.67%). Geographically, two prominent clusters were identified and the distribution of Sickle haemoglobin in the island contrasted markedly with the other haemoglobinopathies. 3/9 homozygous sickle patients and 3/51 Sickle β-thalassaemia patients were receiving regular transfusion. Joint pain was the commonest clinical presentation among all sickle cell disease patients (n=39, 65.0%). Dactylitis was significantly more common in homozygous sickle patients compared with the Sickle β-thalassaemia group (p 0.034). Two genetic backgrounds sickle mutation were identified namely, Arab Indian and Benin. Among the regulators of Foetal hemoglobin in Sickle patients of the present study rs1427407 G>T seemed to be the most prominent modifier, with a significant association with Foetal haemoglobin levels (p 0.04).

Conclusions Overall, the clinical course of the Asian version of Sickle cell disease in Sri Lanka appears to be milder than that described in India.

Background

Sickle Cell Disease (SCD) is the collective term for a group of inherited disorders characterized by mutations in the gene encoding the β-haemoglobin subunit (HBB). The prevalence of the disease is high in sub-Saharan Africa, Middle East, India, Jamaica and Brazil. [1]. Sri Lanka is a multi-ethnic country with a population of 20.4 million, comprised of Sinhalese (74.9%), Tamils (15.2%), Moors (9.3%) and several other minor groups [2].

Sickle haemoglobin (Hb S) was first reported in the country among Sinhalese in 1962 in the Eastern province of the country. [3]. Even though Sri Lanka is geographically adjacent to India, where the prevalence of Hb S is high, particularly among tribal populations, the prevalence of Hb S in Sri Lanka
is lower and is confined mainly to coastal areas [4]. No detailed descriptions of SCD in Sri Lanka are available in the literature, although there are several reports for some sporadic cases of SCD, including homozygous sickle cell anaemia (Hb SS), sickle-β thalassaemia (SBT) and Hb SD disease [5–10]. Currently, SCD patients in Sri Lanka are typically treated in either thalassaemia centres or general paediatric or medical wards. A recent island-wide hospital based epidemiological survey of haemoglobinopathies identified 1774 patients with a haemoglobinopathy. 51 of whom were sickle patients (un specified SCD), confirming that SCD is uncommon in Sri Lanka 2.8% (51/1774). The same survey identified significant inconsistencies in care of SCD patients between centres. [11]. Genetic information including haplotype analysis for SCD in Sri Lanka is scarce, and has been reported for a single patient with SBT [12] only. Hence, in the present study we intend to describe the clinical picture of SCD patients in Sri Lanka, analyze its molecular basis, including the effects of genetic modifiers on the phenotype.

Methods
Study design and population
We conducted a cross-sectional study between December 2016 and March 2019 recruiting patients previously diagnosed with SCD from seven thalassaemia centres in Sri Lanka. The thalassaemia centres were located in the districts of Mahara, Kurunegala, Anuradhapura, Hambantota, Monaragala, Ampara and Batticaloa, All SCD patients were eligible for the study and there were no exclusion criteria. All patients were examined by the study physician and clinical details were obtained using a pre-tested interviewer-administered questionnaire.

Haematological and haemoglobin analyses
A Five ml venous blood sample was collected into EDTA (Ethylenediaminetetraacetic acid) from each participant. Routine haematological measurements were conducted using a Coulter counter Ac•T 5diff OV (Beckman Coulter, Inc., Brea, California, United States). Haemoglobin phenotype was determined by capillary electrophoresis (CE) using Capillarys 2 flex piercing analyzer (Sebia, France). DNA for genetic analyses was extracted by QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) and stored at -20 °C until further use.
Basic Genetic analyses

Classical β- globin haplotyping was performed. Six regions around and within the β globin gene cluster were amplified by the polymerase chain reaction (PCR), using primers from Integrated DNA Technologies, Inc., Iowa, United States. Primer sequences were those referenced by [13]. PCR products of each patient were treated with appropriate restriction enzymes (from Thermofisher scientific) according to manufactures instructions and the resulting fragments were separated on 2% agarose gel. Bands were visualized and photographed by UVP BioDoc-It® Imaging System. Six polymorphic restriction sites were studied; 5’ to ε gene by Hind II, 5, to Gγ gene by Xmn I, within IVS 2 of the Gγ and Aγ genes by Hind III, 3’ to ψβ by Hind II, and IVS 2 of the β gene by Ava II. When the Restriction Fragment Length Polymorphism (RFLP) pattern was heterozygous, the sickle haplotype was determined based on the assumption that common sickle haplotypes were present [14]. Common α + globin gene deletions (3.7 and 4.2 kb) were studied by multiplex GAP polymerase chain reaction [15]. Beta- thalassaemia mutations of the SBT patients were determined by Amplification Refractory Mutation System (ARMS) [16].

Sequencing analyses of Hb SS patients

New generation sequencing (NGS) was done using a customized panel which sequenced 5 regions of the genome of all the Hb SS patients reported in study including; Chromosome 2 (hg 19 Grch build 37) - chr2:60,575,685 – 60,753,050, Chromosome 6 (hg 19 Grch build 37) - chr6:135,281,347 – 135,540,835, Chromosome 11 (hg 19 Grch build 37) - chr11:3,779,641–7,224,114, Chromosome 16 (hg 19 Grch build 37) - chr16: 575,307- 2,619,179 and Chromosome X (hg 19 GrCh build 37) - chrX:11,253,922 – 11,377,717 using Illumina platform (Illumina Miseq). Variations found were annotated with Integrative Genomic Viewer version 2.6 (Broad Institute) using GRCh37 - hg19 - Genome – Assembly by NCBI (National Centre for bio-informatics) as the reference sequence.

Genotyping of Foetal Haemoglobin (Hb F) modifiers among SCD patients

Four known Hb F modifiers (rs1427407 and rs6545816 in BCL11A, rs66650371 in HMIP-2A and rs9402686 in HMIP-2B) were genotyped by Taqman assay real time PCR using Viia 7 Applied Biosystems. One Hb F modifier (rs7482144 in Xmn1-HBG2) was genotyped by RFLP.
Results

Basic demographic data

Between December 2016 and March 2019, 60 SCD patients were recruited for the study. Fifty-one patients (51/60; 85%) were SBT patients and 9 (9/60; 15%) were homozygous Hb SS patients. Homozygosity was confirmed in all 9 patients by typing the sickle mutation rs334 (T > A) at chr11:5227002 (GRCh38.p12) by NGS. There were 30 male and 30 female participants. SCD patients in the present study were living in 10 out of the 25 districts of Sri Lanka. Geographically, two prominent patient clusters were noted and the Southern cluster comprising Hambantota and Moneragala districts accounting for 27 (45.0%) SCD patients was the dominant cluster (Fig. 1). The SCD patients comprised of three ethnic groups; 52 (86.67%) were Sinhalese, 5 (8.33%) were Moors and 3 (5.0%) were Tamils. Non-parametric statistical methods were used since data were not normally distributed.

Haematological data

Basic haematological parameters of those who had not received a blood transfusion in the three months prior to blood sampling are summarized in Table 1. Hb A2 levels were significantly lower among Hb SS group than SBT (p < 0.001) group. Conversely, MCV, MCH and MCHC values were all significantly higher among Hb SS group (p < 0.001). Reticulocyte count was also significantly higher in Hb SS group (p 0.013) suggesting increased rates of haemolysis compared to SBT.

Table 1: Haematological parameters of Hb SS and SBT patients those who had not undergone a blood transfusion within three months prior to data collection.
| Parameter     | Hb SS (n=6) |        | SBT (n=42) |        |
|--------------|-------------|--------|------------|--------|
|              | Mean (SD)   |        | Mean (SD)  |        |
| Hb (g/dl)    |             |        |            |        |
| (13.0-18.0 - Male) | 8.4 (1.1)  | 8.7 (0.2) | 8.5 (0.9)  | 8.2 (1.0)  |
| (11.5 – 16.5 Female) |          |        |            |        |
| Hb A2 (%)    | 1.7 (0.4)   | 1.4 (0.5) | 1.6 (0.4)  | 4.5 (0.5)  |
| (1.5 – 3.2 %) |          |        |            |        |
| Hb F (%)     | 20.6 (1.8)  | 31.9 (0.5) | 24.4 (6.0) | 22.2 (6.4) |
| (< 1.0%)     |            |        |            |        |
| MCV (fl) (80 – 100) | 84.2 (4.3) | 85.0 (9.9) | 84.5 (5.6) | 69.0 (4.3) |
| MCH (pg) (27 – 32 ) | 29.6 (0.5) | 29.9 (2.0) | 29.7 (1.0) | 21.8 (1.7) |
| MCHC (%) (33-35) | 33.0 (0.5) | 33.5 (0.7) | 33.2 (0.6) | 31.5 (0.9) |
| Reticulocytes (%) | 9.6 (2.1) | 6.3 (5.5) | 8.5 (4.5)  | 5.2 (1.9)  |
| (0.5 – 1.5)  |            |        |            |        |
| WBC (×10⁹/L) | 14.0 (8.8)  | 6.7 (0.1) | 11.6 (7.8) | 9.1 (4.1)  |
| (4.5 – 11.0 ) |          |        |            |        |
| PLT (×10³/µL) | 324.0 (178.0) | 252.0 (111.8) | 300 (151.2) | 240.0 (135.9) |
| (150 - 450 ) |            |        |            |        |

Hb, Haemoglobin; Hb A2, Adult Haemoglobin-2; Hb F, Foetal Haemoglobin; MCV, Mean Corpuscular Volume; MCH, Mean Corpuscular Haemoglobin; MCHC, Mean Corpuscular Haemoglobin Concentration; WBC, White Blood Cells; PLT, Platelets. p<0.05 of Mann-Whitney U test was taken as significant

Clinical findings

Age at presentation of all SCD patients was highly variable, ranging from 4 months to 55 years (Mean 9.8 years; SD- 11.3 years). Most of the patients (51.7%; n = 31) had presented with fever, whilst the next common presenting symptoms were joint pain and abdominal pain (26.7%; n = 16). Icterus led to identification of the disease in a further 9 (15%) cases. Six more patients were incidentally diagnosed
whilst investigating anaemia. A further three patients were diagnosed during pregnancy. 
Clinical features of both SBT patients and Hb SS patients are summarized in Table 2. Joint pains were 
the most common clinical symptom observed among all SCD patients. Ischemic cerebrovascular event 
had occurred in one SBT and one Hb SS patient. Similarly, avascular necrosis of the hip was present in 
one Hb SS patient and one SBT patient. Fisher’s exact test showed that the incidence of dactylitis was 
the only clinical feature which was significantly different between Hb SS and SBT patients (p 0.034). 
Splenectomy had been carried out in 1 / 9 Hb SS and 4/51 SBT patients. The exact reason for 
splenectomy and its justification could not be deduced from the clinical records. Four of the 
splenectomized patients had undergone the surgery before the age of 20 years. Three out of 9 
(33.33%) Hb SS and 3/51 (5.88%) SBT patients were on regular blood transfusion (defined as > 8 
transfusions / year). Based on clinical records it appeared that blood transfusions had mostly been 
given when haemoglobin concentration of the patient fell to 6 g/dl or less, although this could not be 
ascertained with certainty. Incidentally, 12 (23.53%) of SBT patients never had any transfusion in 
their lifetime. Forty-one SCD patients (68.3%) in our series had a history of at least one pain event 
(Joint/Abdominal/Chest) in their lifetime, while 19 SCD patients including three Hb SS individuals had 
not experienced any pain events. Cold weather (33.33%, n = 20) was the most frequently identified 
precipitating factor for pain events among SCD individuals, followed by infections (26.32%, n = 15). 
Thirteen (21.66%) SCD patients who had pain crisis reported no obvious precipitant factor for pain 
events. At the time of data collection 26 (43.33%) SCD patients were taking Hydroxyurea. Nineteen 
(31.67%) SCD patients were on Folic acid only. Twenty-eight (48.7%) SCD patients were one penicillin 
prophylaxis. Six SCD patients (10%) were not on any medication.

Table 2: Summary of clinical features observed between SBT group and Hb SS group
| Clinical feature / presentation | SBT group \(n\) | Hb SS group \(n\) | Cumulative figure \(N=60\) | \(^{1}\) Fisher’s exact test \(p\) |
|-------------------------------|----------------|----------------|-------------------------|-------------------------------|
| Joint pain                    | 32 (62.75%)    | 7 (77.78%)     | 39 (65.0%)              | 1.000                         |
| Palpable spleen               | 33 (64.70%)    | 3 (33.33%)     | 24 (60.0%)              | 0.137                         |
| Hospital admission due to pain| 30 (58.82%)    | 5 (55.56%)     | 35 (58.33%)             | 1.000                         |
| Jaundice                      | 23 (45.10%)    | 6 (66.67%)     | 29 (48.33%)             | 0.292                         |
| Major infections              | 17 (33.33%)    | 4 (44.44%)     | 21 (35.0%)              | 0.706                         |
| Recurrent headaches           | 12 (23.53%)    | 2 (22.22%)     | 14 (23.33%)             | 1.000                         |
| Pica                          | 9 (17.65%)     | 2 (22.22%)     | 11 (18.33%)             | 0.664                         |
| Abdominal pain                | 10 (19.61%)    | 0              | 10 (16.67%)             | ---                           |
| Dactylitis                    | 6 (11.76%)     | 4 (44.44%)     | 10 (16.67%)             | 0.034                         |
| Gallstones                    | 9 (17.65%)     | 1 (11.11%)     | 10 (16.67%)             | 1.000                         |
| Pallor                        | 6 (11.76%)     | 3 (33.33%)     | 9 (15.0%)               | 0.125                         |
| Acute chest syndrome          | 6 (11.76%)     | 2 (22.22%)     | 8 (13.33%)              | 0.593                         |
| Vision impairment             | 8 (15.69%)     | 0              | 8 (13.33%)              | ---                           |
| Abdominal distension          | 4 (7.84%)      | 1 (11.11%)     | 5 (8.33%)               | 0.57                          |
| Facial deformities            | 3 (5.88%)      | 0              | 3 (5.0%)                | ---                           |
| Nocturnal enuresis            | 3 (5.88%)      | 0              | 3 (5.0%)                | ---                           |
| Leg ulcers                    | 3 (5.88%)      | 0              | 3 (5.0%)                | ---                           |
| Transient Ischemia Attack     | 1 (1.96%)      | 1 (11.11%)     | 2 (3.33%)               | 0.28                          |

\(^{1}\) Fisher’s exact test \(p<0.05\) was taken as significant

Genetic findings

Thirty-seven (72.55%) SBT patients had IVS 1-5 (G→C) mutation, 11(21.57%) had IVS 1-1 (G→A) mutation, 2 had CD-16 mutation and one SBT patient had CD 41/42 mutation. These are all either \(\beta^0\)
or severe $\beta^+$ mutations, expected to result in disease severity similar to Hb SS. Gap PCR for common $\alpha$+ gene deletions found only 4 (6.67%) SBT patients with 3.7 kb deletions. None of the SCD patients had the 4.2 kb $\alpha$ gene deletion.

Haplotyping by traditional RFLP showed that the sickle mutation occurred on two main beta globin haplotypes in Sri Lanka. Namely Arab-Indian (AI) and Benin. Out of 18 $\beta$ globin haplotypes among the 9 Hb SS patients, 14 were AI haplotype and 4 were Benin haplotype. Presence of AI haplotype and Benin haplotype in Sri Lanka was confirmed with NGS by typing 4 different SNPs (rs3834466, rs28440105, rs10128556 and rs968857) in 9 Hb SS patients as described previously [17]. When looking at the genetic variants that moderate Hb F levels, rs6545816 in BCL11A was found at the highest allele frequency (88%) followed by rs7482144 in Xmn I-HBG2 (47%) (Table 3). Allelic discrimination plot of rs6545816 is shown in Fig 2.

Table 3: Presence and frequency of Hb F determining variants in Sri Lankan SCD patients
| Locus      | Variants | Position on chromosome | Allele change | Genotypes detected |
|------------|----------|------------------------|---------------|--------------------|
| Chromosome 2 |          |                        |               |                    |
| BCL11A     | rs6545816| 60,568,365              | A > C         | CC, n=             |
|            |          |                        |               | AC, n=             |
|            | rs1427407| 60,571,547              | G > T         | GG, n=             |
|            |          |                        |               | GT, n=             |
| Chromosome 6 |          |                        |               |                    |
| HMIP-2A    | rs66650371| 135,460,326-135,460,328| In > Del      | II, n= 5          |
|            |          |                        |               | DI, n= 1          |
|            |          |                        |               | DD, n=             |
| HMIP-2B    | rs9402686| 135,469,509              | G > A         | GG, n=             |
|            |          |                        |               | GA, n=             |
| Chromosome 11 |         |                        |               |                    |
| Xmn I – HBG2 | rs7482144| 5,232,745               | G > A         | GG, n=             |
|            |          |                        |               | GA, n=             |

**Discussion**

Our study is the first description of the genotypic and phenotypic associations of SCD in Sri Lanka.

Haplotype data in our present study sheds new light on the genetic background of Hb S in Sri Lanka.

Both Al and Benin haplotypes of Hb S are common in Saudi Arabia [18, 19]. The presence of Al and Benin haplotypes of Hb S in Sri Lanka suggests that occurrence of Hb S in Sri Lanka is more likely to have originated from Arab migrations than African settlings. Historical records also indicate the existence of Arab settlements near coastal towns of Beruwala, Colombo, Chilaw, Galle, Mannar, Puttalam and Trincomalee by 9th century A.D. [20]. In the present study most of the SCD patients recruited were living fairly close to some of above mentioned coastal areas.

Joint pain was the most common clinical feature observed in both Hb SS (77.78%) and SBT (62.75%) patients. Joint pains are not uncommon among sickle patients in the Indian subcontinent. A recent study from Madhya Pradesh, Central India reported that the incidence of joint pain is over 80% in both
Hb SS and SBT groups [21]. Bone pain reported at high frequencies in Indian SCD patients [22–24], was not present in any participants in our study. Requirement for regular blood transfusions was higher among Hb SS (33.33%) than SBT (5.88%) patients in the present study. These findings differ from a study reported from Madhya Pradesh (India) in which 16.1% of Hb SS and 17.4% of SBT patients were on regular blood transfusion [21]. Furthermore, twelve (23.53%) SBT patients had never received a transfusion in their lifetime. As the indication for blood transfusions were very often physician initiated and there was no defined rationale, these observations need to be interpreted with caution, and suggests the need for clear guidelines on the management of SCD in Sri Lanka, including the use of transfusion.

Only two cases of avascular necrosis of the hip were reported in the present study, which is in contrast to eastern Indian SCD patients, in whom incidences over 10% have been reported across several age groups [25]. Priapism and leg ulcers were not found in our study. There were no deaths in any of the SCD patients reported during the period of observation.

Hb F plays a significant role in ameliorating complications is SCD [26]. In the present study, in patients who were not on transfusion, mean Hb F concentrations were 24.4% and 23.0% in Hb SS and SBT patients, respectively. These values are in accordance with the observations from the Maharashtra (India) but are higher than the values observed in Madhya Pradesh (India) [21, 24]. The Hb F levels are much higher than those found in SCD patients of Sub-Saharan African origin, and levels greater than 20% would typically be associated with less severe clinical picture. Hb F boosting allele “C” of rs6545816 was detected at a much higher frequency in Sri Lankan patients than in patients from the United Kingdom (34%), Tanzania (36%) and Nigeria (35%) [27, 28]. Furthermore, “T” allele of rs1427407 was significantly associated with high Hb F levels (p = 0.04). The presence of common α + gene deletions was surprisingly low in this study. This is in contrast with observations in Western Indian SCD patients in whom the prevalence of α gene deletions was 29/51;56.8% [29]. Similarly, in a study of 60 SCD patients in New Delhi, the prevalence of α globin gene deletions was 18/60;30.% [30].

One of the most notable observational findings of our study was the gross inconsistency in the clinical
management of SCD patients across the different centres across Sri Lanka. Usage of hydroxyurea was not consistent among sickle patients in these centres. Equally, the practice of blood transfusions was also very variable, reflecting perhaps the lack of familiarity in the management of the disease by the attending medical teams and the need for national guidelines on the management of patients with SCD.

Conclusions
Overall, though the numbers may be limited the clinical course of the Asian version of SCD in Sri Lanka appears to be milder than that described from India. High HbF levels are common and deletional α thalassaemia rarer. The natural selection, early migratory patterns of Arabs and settlements may explain why SCD is found mostly in coastal regions and low lands of Sri Lanka. We plan to undertake further work to elucidate the causative elements responsible for the milder appearance of SCD in Sri Lanka.

Abbreviations
SCD: Sickle Cell Disease; HBB: β-haemoglobin subunit; Hb S: Sickle Haemoglobin; Hb SS: homozygous Sickle Cell Anaemia; SBT: Sickle β-thalassaemia; EDTA: Ethylenediaminetetraacetic acid; CE: Capillary Electrophoresis; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; ARMS: Amplification Refractory Mutation System; NGS: New Generation Sequencing; Hb F: Foetal Haemoglobin

Declarations

Ethics approval and consent to participate
Ethical approval for the study was obtained from Faculty of Medicine, University of Kelaniya, Sri Lanka (P/01/01/2016). Informed written consents form adult SCD patients and assents from the parents of the participating SCD children were obtained before enrollment for the present study.

Consent for publication
Not applicable

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Competing interests

All authors declare that they have no competing interests

Funding

This research was funded by National Research Council Sri Lanka, grant number NRC 16-001 and The APC was not funded by any funding agency

Author Contribution

TD has contributed to haplotype sickle haemoglobin with RFLP, total data curation, analyze the data and write the original manuscript. AP has contributed to design the research, clinical data collection, supervise the overall work and to revise and edit the manuscript. DR, AA and AM have contributed to revise and edit the manuscript. FS has contributed to NGS of Hb SS patients, SM has contributed to genotyping of Hb F markers, RR has contributed to Gap PCR of common α plus gene deletions and ARMS PCR for β-thalassaemia mutations, DM, UN, US, YC, KP, SP, SB, CE, PD, MW and AAA have contributed to clinical data collection and edit the manuscript.

Acknowledgement

Not applicable

References

1. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF et al: Sickle cell disease. Nature Reviews Disease Primers 2018, 4:18010.

2. Lanka DocaS-S: Census of population and housing (Table A3). In. Sri Lanka; 2012.

3. De Silva CC, Bulugahapitiya TD, De Silva J, Wickremasinghe RL, Jonxis HP: Sinhalese family with haemoglobin S. British medical journal 1962, 1(5291):1519-1521.

4. Premawardhena A, Allen A, Piel F, Fisher C, Perera L, Rodrigo R, Goonathilaka G, Ramees L, Peto T, Olivieri N et al: The evolutionary and clinical implications of the uneven distribution of the frequency of the inherited haemoglobin
variants over short geographical distances. *British journal of haematology* 2017, **176**(3):475-484.

5. Lucas GN, Jayawardena DR: A case of homozygous sickle cell disease in Sri Lanka. *The Ceylon medical journal* 1991, **36**(4):172-174.

6. Thalagahage KH, Jayaweera J, Kumbukgolla W, Perera N, Thalagahage E, Kariyawasam J, Dissanayake V: HbS/D-Punjab Disease: Report of 3 Cases from Sri Lanka. *Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion* 2018, **34**(2):350-352.

7. Tudawe MN, Senadheera NB, Gooneratne LV: Variations in the presentation of sickle cell beta thalassaemia--a report of two cases. *The Ceylon medical journal* 2005, **50**(3):134-135.

8. Nagaratnam N: Hemoglobinopathies in Sri Lanka and their anthropological implications. *Hemoglobin* 1989, **13**(2):201-211.

9. Karunatilake H, Vithiya K, Malavan R, Natalia H, Ratnayake H: Exchange transfusion for intrahepatic cholestasis due to sickle beta thalassaemia. *The Ceylon medical journal* 2009, **54**(3):95-96.

10. Premathilaka LHRA, Lakmini MS, Darshana LGT, Nawaratne SB, Mettananda S, De Silva S, Premawardhena A: Stroke in sickle beta thalassemia - a case report highlighting pitfalls in management in a low prevalence country. *Sri Lanka Journal of Medicine* 2018, **26**:55.

11. Premawardhana AP, Mudiyanse R, De Silva ST, Jiffry N, Nelumdeniya U, de Silva U, Lamabadusuriya SP, Pushpakumara K, Dissanayaka R, Jansz M et al: A nationwide survey of hospital-based thalassemia patients and standards of care and a preliminary assessment of the national prevention program in Sri Lanka. *PloS one* 2019, **14**(8):e0220852.
12. Fisher CA, Premawardhena A, de Silva S, Perera G, Rajapaksa S, Olivieri NA, Old JM, Weatherall DJ: The molecular basis for the thalassaemias in Sri Lanka. British journal of haematology 2003, 121(4):662-671.

13. Rahimi Z, Karimi M, Haghshenass M, Merat A: Beta-globin gene cluster haplotypes in sickle cell patients from southwest Iran. American journal of hematology 2003, 74(3):156-160.

14. Steinberg MH, Hsu H, Nagel RL, Milner PF, Adams JG, Benjamin L, Fryd S, Gillette P, Gilman J, Josifovska O et al: Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia. American journal of hematology 1995, 48(3):175-181.

15. Chong SS, Boehm CD, Higgs DR, Cutting GR: Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. Blood 2000, 95(1):360-362.

16. Old JM, Khan SN, Verma I, Fucharoen S, Kleanthous M, Ioannou P, Kotea N, Fisher C, Riazuddin S, Saxena R et al: A multi-center study in order to further define the molecular basis of beta-thalassemia in Thailand, Pakistan, Sri Lanka, Mauritius, Syria, and India, and to develop a simple molecular diagnostic strategy by amplification refractory mutation system-polymerase chain reaction. Hemoglobin 2001, 25(4):397-407.

17. Shaikho EM, Farrell JJ, Alsultan A, Qutub H, Al-Ali AK, Figueiredo MS, Chui DHK, Farrer LA, Murphy GJ, Mostoslavsky G et al: A phased SNP-based classification of sickle cell anemia HBB haplotypes. BMC Genomics 2017, 18(1):608-608.

18. Jastaniah W: Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med 2011, 31(3):289-293.

19. Alsultan A, Alabdulaali MK, Griffin PJ, Alsuliman AM, Ghabbour HA, Sebastiani P,
Albuali WH, Al-Ali AK, Chui DHK, Steinberg MH: Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign. British journal of haematology 2014, 164(4):597-604.

20. Dasanayaka R: Muslim Trade Relations with Sri Lanka: Historical Respective-In Sinhala: Ada Sanda Saha Tharadiya; 2019.

21. Yadav R, Lazarus M, Ghanghoria P, Singh M, Gupta RB, Kumar S, Sharma RK, Shanmugam R: Sickle cell disease in Madhya Pradesh, Central India: A comparison of clinical profile of sickle cell homozygote vs. sickle-beta thalassaemia individuals. Hematology (Amsterdam, Netherlands) 2016, 21(9):558-563.

22. Patel J, Patel B, Serjeant GR: The Bone Pain Crisis of Sickle Cell Disease and Malaria: Observations from Gujarat, India. Indian J Community Med 2017, 42(3):167-169.

23. Kulozik AE, Bail S, Kar BC, Serjeant BE, Serjeant GE: Sickle cell-beta+ thalassaemia in Orissa State, India. British journal of haematology 1991, 77(2):215-220.

24. Jain D, Warthe V, Dayama P, Sarate D, Colah R, Mehta P, Serjeant G: Sickle Cell Disease in Central India: A Potentially Severe Syndrome. Indian journal of pediatrics 2016, 83(10):1071-1076.

25. Mashon RS, Dash PM, Khalkho J, Dash L, Mohanty PK, Patel S, Mohanty RC, Das BS, Das UK, Das PK et al: Higher fetal hemoglobin concentration in patients with sickle cell disease in eastern India reduces frequency of painful crisis. European journal of haematology 2009, 83(4):383-384.

26. Piel FB, Steinberg MH, Rees DC: Sickle Cell Disease. New England Journal of Medicine 2017, 376(16):1561-1573.
27. Gardner K, Fulford T, Silver N, Rooks H, Angelis N, Allman M, Nkya S, Makani J, Howard J, Kesse-Adu R et al: g(HbF): a genetic model of fetal hemoglobin in sickle cell disease. *Blood advances* 2018, 2(3):235-239.

28. Adeyemo TA, Ojewunmi OO, Oyetunji IA, Rooks H, Rees DC, Akinsulie AO, Akanmu AS, Thein SL, Menzel S: A survey of genetic fetal-haemoglobin modifiers in Nigerian patients with sickle cell anaemia. *PLoS one* 2018, 13(6):e0197927.

29. Mukherjee MB, Surve R, Tamankar A, Gangakhedkar RR, Ghosh K, Lu CY, Krishnamoorthy R, Colah R, Mohanty D: The influence of alpha-thalassaemia on the haematological & clinical expression of sickle cell disease in western India. *The Indian journal of medical research* 1998, 107:178-181.

30. Pandey S, Pandey S, Mishra RM, Sharma M, Saxena R: Genotypic influence of α-deletions on the phenotype of Indian sickle cell anemia patients. *Korean J Hematol* 2011, 46(3):192-195.

Figures
Figure 1

Locations from which SCD patients were reported in present study (each dot represents one patient)
Allelic discrimination of the marker Hb F marker rs6545816 of SCD patients of the present study.